As reported on the MedicalXpress website, research from the University of British Columbia is …
“The latest study to examine how tiny amounts of psychedelics can impact mental health provides further evidence of the therapeutic potential of microdosing.
Published in Scientific Reports this week, the study followed 953 people taking regular small amounts of psilocybin and a second group of 180 people who were not microdosing. This research, led by University of British Columbia Okanagan’s Dr. Zach Walsh and doctoral student Joseph Rootman, is the latest study to come from the Microdose.me project.
For the 30-day study, participants were asked to complete a number of assessments that tapped into mental health symptomology, mood and measures of cognition. For example, a smartphone finger tap test was integrated into the study to measure psychomotor ability, which can be used as a marker for neurodegenerative disorders including Parkinson’s disease.
Those microdosing demonstrated greater improvements in mood, mental health and psychomotor ability over the one-month period, compared to non-microdosing peers who completed the same assessments …”
You can read more from here.
Other posts about collaborative practice:
The Industrialisation of Care: counselling, psychotherapy and the impact of IAPT
Psychotherapy Relationships that Work: Volume 1: Evidence-Based Therapist Contributions … 3rd Edition
Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA